A Retrospective Study of Propranolol Therapy in 635 Infants with Infantile Hemangioma

2014 ◽  
Vol 32 (1) ◽  
pp. 151-152 ◽  
Author(s):  
Yongqi Luo ◽  
Yinghong Zeng ◽  
Bin Zhou ◽  
Jianping Tang
Keyword(s):  
Retrospective Study ◽  
Infantile Hemangioma ◽  
Propranolol Therapy

A Retrospective Study of Propranolol Therapy in 109 Infants with Infantile Hemangioma

2012 ◽  
Vol 30 (2) ◽  
pp. 270-272 ◽  
Author(s):  
Li-qiang Gan ◽  
Si-li Ni ◽  
Qi Tan ◽  
Hua Wang
Keyword(s):  
Retrospective Study ◽  
Infantile Hemangioma ◽  
Propranolol Therapy

Effects of propranolol therapy in Moroccan children with infantile hemangioma

2018 ◽  
Vol 25 (8) ◽  
pp. 449-451 ◽  
Author(s):  
A. Lahrichi ◽  
F. Hali ◽  
K. Baline ◽  
F.Z. El Fatoiki ◽  
S. Chiheb ◽  
...  
Keyword(s):  
Infantile Hemangioma ◽  
Moroccan Children ◽  
Propranolol Therapy

scholarly journals Effects of Propranolol on Neurodevelopmental Outcomes in Patients with Infantile Hemangioma: A Case-Control Study

2018 ◽  
Vol 2018 ◽  
pp. 1-6
Author(s):  
Chuan Wang ◽  
Qi Wang ◽  
Bo Xiang ◽  
Siyuan Chen ◽  
Fei Xiong ◽  
...  
Keyword(s):  
Treatment Duration ◽  
Infantile Hemangioma ◽  
Control Group ◽  
Healthy Children ◽  
Neurodevelopmental Outcomes ◽  
Obvious Effect ◽  
Negative Effect ◽  
Initiation Of Therapy ◽  
Propranolol Therapy ◽  
Oral Propranolol

Background. The aim of this study was to examine whether oral propranolol has any effect on neurodevelopment outcomes in young children with problematic infantile hemangiomas (IHs). Methods. Thirty-six children with a diagnosis of problematic IH who were treated with oral propranolol were compared with 34 healthy children with no history of propranolol therapy. Patients received propranolol therapy for at least 3 months. Gesell developmental schedules (GDS) were used to evaluate neurodevelopment outcomes in the two groups. The scores of each GDS domain were compared between the two groups. Results. There were no significant differences in developmental quotient (DQ) values for any of the five domains between the patients and healthy controls (P<0.05). Multiple stepwise regression analyses showed that none of the domains in the control group were influenced by the children’s gender or age (P<0.05). In addition, we found that gender, age at the initiation of therapy, age at the time of the neurodevelopment test, and treatment duration had no effect on any domain of the GDS in the patient group (P>0.05). Conclusion. Propranolol has no obvious effect on neurodevelopmental outcomes in children. Early treatment and treatment duration had no negative effect on central nervous system (CNS) development.

scholarly journals Propranolol Therapy for Reducing the Number of Nasal Infantile Hemangioma Invasive Procedures

2014 ◽  
Vol 140 (3) ◽  
pp. 220 ◽  
Author(s):  
Jonathan A. Perkins ◽  
Brian S. Chen ◽  
Babette Saltzman ◽  
Scott C. Manning ◽  
Sanjay R. Parikh
Keyword(s):  
Infantile Hemangioma ◽  
Invasive Procedures ◽  
Propranolol Therapy

scholarly journals The Impact of Combined Steroid-propranolol Therapy on the Involution of Infantile Hemangioma

2020 ◽  
Vol 6 (4) ◽  
pp. 397
Author(s):  
Mosaad Abdel Hameed Soliman ◽  
Khalid Abdel Aziz Mowafy ◽  
Mohamed Adel Abdel Maksoud ◽  
Amr Mostafa Elshafey ◽  
Nashaat Abdrabo Elsaadany ◽  
...  
Keyword(s):  
Infantile Hemangioma ◽  
The Impact ◽  
Propranolol Therapy

scholarly journals Infantile hemangioma and oral propranolol therapy

2015 ◽  
pp. 148-51
Author(s):  
Mustafa Dilek ◽  
Mervan Bekdaş ◽  
Sevil Bilir Göksügür ◽  
Fatih Demircioğlu ◽  
Zehra Karataş ◽  
...  
Keyword(s):  
Infantile Hemangioma ◽  
Propranolol Therapy ◽  
Oral Propranolol

scholarly journals PHACE Syndrome in a Child with Structural Malformations of the Brain

2020 ◽  
Author(s):  
Utku Aygüneş ◽  
Melih Timuçin Doğan ◽  
Avni Merter Keçeli
Keyword(s):  
Magnetic Resonance ◽  
Cardiac Involvement ◽  
Brain Magnetic Resonance Imaging ◽  
Infantile Hemangioma ◽  
Phace Syndrome ◽  
The Face ◽  
Posterior Fossa Malformations ◽  
Noticeable Reduction ◽  
The Brain ◽  
Propranolol Therapy

AbstractPHACE syndrome is an acronym that describes a neurocutaneous condition, consisting of posterior fossa malformations that coexist with large facial hemangiomas, eye anomalies, and cardiac/aortic defects. The prognosis of the disease has not been clearly identified. There appears to be a risk of stroke in children with arterial anomalies. Radiological examinations play a considerable role in determining the degree of intracranial, cardiac involvement and the probable complications. We report a 4-month-old boy with PHACE syndrome that has been diagnosed through a large segmental infantile hemangioma involving the eye and over the left half of the face in brain magnetic resonance imaging and magnetic resonance angiography findings. One month after starting propranolol therapy, there was a noticeable reduction in the size of the lesions. Almost complete resolution of the hemangioma was seen after a 6 months of propranolol therapy.

Recurrence rate of infantile hemangioma after oral propranolol therapy

2020 ◽  
Author(s):  
Giovanni Frongia ◽  
Ji-Oun Byeon ◽  
Arianeb Mehrabi ◽  
Patrick Günther
Keyword(s):  
Recurrence Rate ◽  
Infantile Hemangioma ◽  
Propranolol Therapy ◽  
Oral Propranolol
Sign in / Sign up

Export Citation Format

Share Document